11th June, 2021

The Manager The Manager

BSE Limited The National Stock Exchange of India Limited
Corporate Relationship Department Exchange Plaza,
P. J. Towers, Dalal Street, Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 001. Mumbai – 400 051.

BSE Scrip Code No. 524280 NSE Symbol : KOPRAN

Dear Sir/Madam,

Sub: Investors Presentation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)

Regulations, 2015 as amended, please find enclosed herewith presentation on Q4FY21
earning of the Company. A copy of the said presentation is also being uploaded on the
Company's website www.kopran.com.

Kindly dissipate the information on Exchange website.

Regards,

For Kopran Limited

Sunil Sodhani
Company Secretary & Compliance Officer

Encl.: a/a.

KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111
Fax: (022) 2495 0363 Website: www.kopran.com CIN – L 24230 MH 1958 PLC 011078.
Works:• Village Savroli, Taluka: Khalapur, District: Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337• Fax: (02192) 274025
An Integrated Global Pharmaceutical Company

Growth-Driven.
Future-Focused.
Kopran Limited
Quarterly Presentation
JUNE 2021
NSE ticker: KOPRAN
BSE ticker: 524280
Bloomberg ticker: KOP:IN

A Parijat Enterprise Company

 Safe Harbour Statement 2

This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or
placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any
part thereof) delivered or supplied, should not be deemed to constitute an offer.
No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy,
completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only
current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be
‘forward-looking statements’, including those relating to the general business plans and strategy of Kopran, its future financial
condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements
which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, among many others, or
similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and
other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the
forward-looking statements. These risks and uncertainties include, but are not limited to, risks with respect to API and Formulation
businesses.
Kopran may alter, modify, or otherwise change in any manner, the content of this presentation, without obligation to notify any
person of such revision or changes. This presentation cannot be copied and disseminated in any manner.
 Kopran Limited A Global Pharmaceutical Company 3

Who we are?
An integrated pharmaceutical Company, committed to supply International
Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally
State-of-the-art manufacturing facilities and products with various accreditations
and approvals by major global regulatory authorities
Formulations vertical is operated through Kopran Limited
APIs vertical is being operated under Kopran Research Laboratories Ltd. (KRLL), a
wholly-owned subsidiary of Kopran Limited

Presence across pharmaceutical value chain

50+ Nations − export reach
Intermediate Technology-focused Company
APIs* Formulations* Packaging Marketing Distribution
Chemicals

Serving Regulated and Non-

Regulated markets
* Our presence across two major verticals in the pharmaceutical value chain
 APIs Business Overview 4

Kopran Research Laboratories Ltd.

Dedicated and versatile Product Segments,

facilities for: Anti-hypertensive
Atenolol
Macrolides
Pregabalin
Neuromodulator
Cephalosporins - Non-Sterile
Urological
& Sterile
Anti-infective/Anti-acne
Macrolides
Sterile Carbapenems
Granules
Facility: Sterile Cephalosporins
Located at MIDC Mahad, Maharashtra, Sterile Carbapenems
Anti-thrombosis
11,900 sq. mts. built-up area Multipurpose plants
162 kl Capacity Gastroenterology
Pilot plants
API Vertical
Development, manufacturing and sale of
diverse APIs and Advanced Intermediates Products
One of the leaders in Atenolol Accreditations:
20+ commercialised
One of the major players in Sterile The plant has been approved by
Carbapenems
World-class facility and quality systems
20 DMFs Filed

Catering export and domestic market US FDA* EU GMP* WHO GMP COFEPRIS
& KFDA*

*except for sterile block

 APIs Focus Areas 5

Process and yield improvement:

Initiatives undertaken continuously for improving the existing product line

US and other Regulated markets Emphasis on exports:

Leveraging expertise and capabilities by exploring,
• 7 USDMF Filed (Atenolol, Pregabalin, developing and commercialising products
US FDA Azithromycin, Metoprolol Tartrate, Atenolol – Focus on improving its share in remunerative export
Metoprolol Succinate, Doripenem & Anti-hypertensive Drug market
Biapenem). Ticagrelor will be filed by
31st December 2021 and Rivaroxaban Expected to gain Active engagement with large companies to secure
will be filed by 30th June 2021 in US a major market share of long-term arrangement
• 1 Approved (Atenolol) the US market in next
two years
Received approval from Develop blockbuster products:
• No Approval in Last Quarter Amlodipine US FDA, European FDA Target Regulated markets through a strong pipeline on
EU CEP Besilate will be filed in May 31, 2021. and Chinese SFDA blockbuster products
Metoprolol succinate will be filed in June Build Anti-diabetic and Anti-thrombosis
30, 2021 and Metoprolol Tartrate will be
product portfolio
filed in September 30, 2021
• 4 Approved Developing the entire range of carbapenems

6 products 8 products
1 product
validation R&D
commercialised
batches taken in completed in
in FY 2020-21
FY 2020-21 FY 2020-21
 APIs Products Developed/Under Development 6

Products under
Pipeline Therapeutic Category R&D Scaleup Validation Commercialization

Biapenem Carbapenem Completed Completed Completed Q2 FY 21-22

Tebipenem Carbapenem Completed Completed Completed

Faropenem# Carbapenem Completed Completed Completed Q3 FY 21-22

Imipenem NS$ Carbapenem Completed Completed Q4 FY 21-22 Q1 FY 2022

Ertapenem$ Carbapenem Q1 FY 21-22 Q2 FY 21-22 Q3 FY 21-22 Q4 FY 21-22

Ticagrelor$ Anti-thrombotic Completed Completed Completed Q2 FY 21-22

Rivaroxaban$ Anti-icoagulant Completed Completed Completed Q3 FY 21-22

Apixaban$ Anti-coagulant Completed Completed Q2 FY 21-22 Q3 FY 21-22

Empagliflozin$ Anti-diabetic Q1 FY 21-22 Q2 FY 21-22 Q3 FY 21-22 Q4 FY 21-22

Dapagliflozin$ Anti-diabetic Q1 FY 21-22 Q2 FY 21-22 Q3 FY 21-22 Q4 FY 21-22

Canagliflozin$ Anti-diabetic Q2 FY 21-22 Q2 FY 21-22 Q3 FY 21-22 Q4 FY 21-22

Nitroxoline# Urological Completed Completed Completed Completed

#Ramping up the production capacity to meet the demand

$Creating infrastructure in the existing plant and increasing the capacity
 Operational Highlights
APIs Segment-wise Revenue Mix 7

Q3 FY 2020-21 (₹ Lakhs) Q4 FY 2020-21 (₹ Lakhs)

Advance
Intermediate Steriles Advance Intermediate
Cepholosphorin Urological
Urological

Steriles 43.02 -11.14

105.84
Cepholosphorin 702.83 Anti-hypertensive 1,153.85 Anti-hypertensive
832.15 363.63
Anti-thrombosis
1,418.22 32.1
Steriles Gastroenterology
Carbapenems 739.8 52.44
Gastroenterology
83.69 Anti-infective/
72.35 Anti-acne
Other Products 307.94 6.79
Sales Anti-thrombosis
1,930.04
317.03
Steriles
Neuromodulator Carbapenems*

3,428.68 Macrolides
42.06
3,084.68 Macrolides 326.72
Other Product
Sales
Neuromodulator

Total ₹ 6,882.17 Lakhs Total ₹ 8,150.52 Lakhs

* Carbapenem is manufactured as per the planned campaigns. The lower contribution from Carbapenem in Q3 is due to disruption of campaigns owing to COVID-19.
 Operational Highlights
APIs Market-wise Revenue mix 8

Q3 FY 2020-21 (₹ Lakhs) Q4 FY 2020-21 (₹ Lakhs)

Local Sales

2,790.88 Local Sales

1,640.09

Export Sales
Export Sales 4,952.91
5,374.83

Total ₹ 6,593 Lakhs Total ₹ 8,165.71 Lakhs

 Way Forward
Develop niche and blockbuster products:
Developing complete range of Carbapenams to solidify the
Company’s position in the segment
Developing Anti-thrombosis and Anti-diabetic portfolio
US Market:
Plan to capture major share of the US Atenolol market in the next
two years
To achieve this feat, the Company is actively engaged with major
players in the US for supply of Atenolol
Plans to file DMFs for all new products being developed
9
Improve facility and enhance capacity:
Undertook upgradation and expansion of 3 blocks at Mahad facility in
Q4 to cater the increasing demand of existing products and
manufacture new molecules that are being developed.
The planned expansion of all plants except sterile started production
in April/May. The production of sterile shall start in second half of
June.
The Company has undertaken expansion of non sterile plant which
shall be completed by Q3 FY 2021-22.
Developing Panoli site as an API/intermediate facility, which is
expected to be operational by Q3/Q4 FY 2021-22.
The Company is evaluating further expansion of its capacity under
newly launched PLI scheme and the same shall be finalised by July.
Penetrate deeper in Regulated markets:
Plans to file DMFs for all new molecules in Regulated markets,
thereby gaining a significant share in the market
 Formulations Business Overview 10

Accreditations:
Kopran Limited
Approved by 12 countries including MHRA (UK),
SAPHRA South Africa (formerly MCC), TMDA Tanzania
(formerly TFDA), NDA Uganda, PPB Kenya, MCAZ
Dedicated Facilities: Zimbabwe,
MOH Oman, MOH Iraq, FMHACA Ethiopia, MOH
Penicillin-based Finished Yemen, FDA Philippines, TGA Australia, MOH Ivory
Dosage Forms Coast
Non-Penicillin-based GMP Certification by FDA, Government of Maharashtra
Finished Dosage Forms WHO GMP Certification by CDSCO, Government of
Facility: India
Located at Khopoli, Maharashtra,
DPM Ivory Coast and Health Canada (Canada)
11,432 sq. mts. of built-up area
Formulations Vertical:
Development and manufacturing of
oral solid dosages and dry powder Product Segments:
formulations for both Penicillin- and
Non-Penicillin-based drugs Penicillin-based Finished Non-Penicillin-based Finished Capacity:
Dosage Forms Dosage Forms
Catering 100% export markets of both Penicillin-based Finished Dosage Forms
Regulated and Anti-infective Macrolides
Amoxycillin Anti-hypertensive 1,747 million Capsules
Non-Regulated markets
Ampicillin Cardiovascular 31 million bottles of Dry Syrup
Manufacturers of more than 100
Cloxacillin Anti-helmentics 1,553 million Tablets
dosages meeting the standards of
international markets which includes Amoxy Clauv Anti-histamine Non-Penicillin-based Finished Dosage Forms
Tablets, Capsules, Dry Powder and EDS 2,000 million Tablets (uncoated)
Suspension Anti-diabetic 1,000 million Tablets (coated)
CNS 947 million Capsules
Pain Management
Gastroenterology
 Formulations Focus Areas and Output
Process/Technology and Yield Improvement:
Continuous measures taken towards process/technology and yield
improvement for making products more competitive and profitable
Automisation and expansion of capacities for:
Increase output
Improve efficiency across value chain
Reduce variable cost
Emphasis on Regulated Market:
Develop products/formulations that match references/innovators'
products for the Regulated markets
Canada and the UK
o Markets largely dominated by contract manufacturing
business
o Canada Filings 01 product 3 strengths Q4 FY 2020-21
South Africa
o South Africa Filings 03 filings in this Q4 FY 2020-21
11
Development of Products and Dossiers for
Non-Regulated Market:
Develop products/formulations and file Dossiers in Non-
Regulated markets to gain a significant market share
Filed 54 dossiers in Q4 FY 2020-21
Growing Into New Markets:
French West Africa, South-East Asia and few Latin American
markets are the focus countries for expanding our presence and
are at the forefront of formulation business
Dossiers filed in Africa & French
31 West Africa region
Dossiers filed in South East Asia
17 region
Dossiers filed in Latin America
6 region
Aggressively Target Tender Markets:
Actively participate in all tenders in African region for
products in which company is present
 Operational Highlights
Formulations Region-wise Sales Break-up 12

Q3 FY 2020-21 (₹ Lakhs) Q4 FY 2020-21 (₹ Lakhs)

Southeast UK UK
Southeast Asia
Asia
427.96 472.16
433.22 361.1

South
South
Africa
1,249.37
Africa 931.61

39.55
Local 28.23 Local 3,470.47 Africa
Latem 46.79 125.56
Latem

2,732.58 Africa

Total ₹ 4,533.53 Lakhs Total ₹ 5,785.05 Lakhs

 Operational Highlights
Formulations Product-wise Sales Break-up 13

Q3 FY 2020-21 (₹ Lakhs) Q4 FY 2020-21 (₹ Lakhs)

Pen Plant
1,047.35

2,027.67
Pen Plant *

3,713.17
Non Pen

3,383.91
Non Pen

Total ₹ 4,431.26 Lakhs Total ₹ 5,740.84 Lakhs

*Penecillin products’ demand was lower due to COVID-19. However, we anticipate demand to pick up from Q1 FY 2021-22.
 Way Forward
Automisation of
manufacturing and packaging
line to increase output of
Regulated markets
finished products, efficiency
across production chain and
reduce variable and
manpower cost
14
Developments of products
and dossiers
To actively participate in
various tenders in the
Non-Regulated markets African region and add
4 dossiers filed in Q4 54 dossiers filed in Q4 more products to
FY 2020-21 FY 2020-21
13 dossiers filed in FY 2020-21 211 dossiers filed in
product portfolio
FY 2020-21
Execute large
tenders won in SADC
Region, Tanzania,
Ethiopia
 15

Financial Performance
 Financial Highlights Quarterly Snapshot 16

Sales/Other Income (₹ Lakhs) EBIDTA * (₹ Lakhs)

2,668.19 2432.33
2,535.46
2,363.45
14,454.98
12,440.21 12,454.44 11,630.41
8,755.77
1,108.23

Q-4 Q-1 Q-2 Q-3 Q-4 Q-4 Q-1 Q-2 Q-3 Q-4
2019-20 2020-21 2020-21 2020-21 2020-21 2019-20 2020-21 2020-21 2020-21 2020-21

*EBIDTA including other incomes

Finance Costs (₹ Lakhs) Net Profit/(Loss) (₹ Lakhs)

222.83
1,656.74
186.1 1568.52 1,535
174.2 1423.13
141.69
121.89

481

Q-4 Q-1 Q-2 Q-3 Q-4 Q-4 Q-1 Q-2 Q-3 Q-4
2019-20 2020-21 2020-21 2020-21 2020-21 2019-20 2020-21 2020-21 2020-21 2020-21

Margins impacted due to export incentive not accounted for in Q4, Since the govt has not declared the rates of benefit and as a result EBITDA and Profits are lower.
Due to shutdown for expansion and upgradation of plant at Mahad, production was lower which affected the profit for the Quarter.
Financial Highlights Y-o-Y Snapshot 17

Sales/Other Income (₹ Lakhs) EBIDTA * (₹ Lakhs)

50,980.04 9,999.43

36,095.99 36,013.01
32,947.82 32,430.42
4,040.17 3,841.47
3,308.51 3,139.82

2016-17 2017-18 2018-19 2019-20 2020-21

2016-17 2017-18 2018-19 2019-20 2020-21
*EBIDTA including other incomes

Net Profit/(Loss) (₹ Lakhs)

Finance Costs (₹ Lakhs)
1,370.17
6,183.39

859.51 899.06 891.17

623.88 2,377
1,989 2,055 2,120

2016-17 2017-18 2018-19 2019-20 2020-21

2016-17 2017-18 2018-19 2019-20 2020-21
 Financial Ratios Building Shareholder Value Year on Year… 18

EBDITA & EBDITA Margin (₹ Lakhs, %) RoE (%) Total Debt/Equity (X)
RoCE (%)

19.61%
9,999.43
0.71

29.9 0.57
0.51
11.19% 10.67% 0.41
10.04% 9.68% 25.23
3,139.82 4,040.17 3,841.47 15.3
3,308.51 12.71 14.5 0.26
12.23
15.95 14.1
14.2 11.18

2016-17 2017-18 2018-19 2019-20 2020-21 2016-17 2017-18 2018-19 2019-20 2020-21 2016-17 2017-18 2018-19 2019-20 2020-21

EBDITA EBDITA Margin Return on Networth/Equity

Return on Capital Employed
 Consolidated Financial Highlights 19

(₹ Lakhs)

Particulars FY 2020-21 FY 2019-20 FY 2018-19 FY 2017-18

Equity Share Capital 4,325.16 4,324.89 4,324.89 4,324.89

Other Equity 20,177.88 14,643.12 12,522.68 10,145.94

Networth 24,503.04 18,968.01 16,847.57 14,470.83

Fixed Assets (net) 15,508.37 14,139.16 13,691.55 11,436.93

Borrowings 6,429.49 7,806.19 8,656.32 8,203.51

Sales/Other Income 50,980.03 36,013.01 36,095.99 32,430.42

EBIDTA 9,999.43 4,695.65 4,913.68 4,005.36

Finance Costs 623.88 891.17 899.06 859.51

Depreciation 1,019.18 957.69 873.92 851.29

Tax Expenses 2,172.98 726.34 763.95 239.90

Net Profit/(Loss) 6,183.39 2,120.45 2,376.75 2,054.66

Earning Per Share (Rs.) 14.24 4.86 5.55 4.74

 Governance Board of Directors 20

Mr. Surendra Somani Mr. Adarsh Rajendra Somani Mrs. Mamta Biyani Mr. Narayan Atal
Executive Vice Chairman Director Independent Director Independent Director

Dr. Siddhan Subramanian Dr. Sunita Banerji Mr. Susheel Somani Mr. Varun Surendra Somani
Independent Director Independent Director Director Director
 Ownership Structure 21

Kopran
Shareholding Pattern (%)
Limited
2.41

Kopran Research
Kopran
Laboratories Kopran (H.K.)
Lifesciences
Limited* Limited 43.78
Limited

53.82

Kopran (UK)
Limited

Promoters Non-Institutions Financial Institutions

 Contact Us 22

About Kopran Limited:

Kopran Limited is an integrated Pharmaceutical
Company, committed to manufacturing and
supplying International Quality Formulations and
APIs worldwide. Kopran's manufacturing facilities
and products have accreditations across all the
continents. Research & Development for New
Products and Processes for both Formulations &
APIs form the strategy of Kopran's growth.

Registered Office: For more information about us,

Parijat House,
1076, Dr. E. Moses Road,
Worli, Mumbai − 400 018,
Maharashtra (India)
Corporate Identification No.:
L24230MH1958PLC011078
please visit www.kopran.com
or contact:
Name: Sunil Sodhani
Tel.: +91 8692991999
Email: sunil@kopran.com
Thank You